The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis

By sjmartinez • October 31, 2023

Tejeda-Munoz N, Azbazdar Y, Monka J, Binder G, Dayrit A, Ayala R, O'Brien N, De Robertis EM. The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis. Elife. 2023 Oct 30;12:RP89141. doi: 10.7554/eLife.89141. PMID: 37902809; PMCID: PMC10615368.

Tags: cancer biology, colorectal cancer, developmental biology, Hematology/Oncology, lysosomes, macropinocytosis, Publications, Wnt signaling, Xenopus, β-catenin

Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study

Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, Nadler E, Patel SP, Peters S, Ricciuti B, Gautam A, Emeribe U, Luciani-Silverman[...]

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]